See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Alzheimer Vaccine ABvac40 Shows Potential to Slow Cognitive Decline in Phase 2 Study

Summary by neurologylive.com
Data presented at AAIC 2025 from a phase 2 study suggest that ABvac40 may slow cognitive decline in patients with Alzheimer disease, particularly among those who developed higher antibody levels.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

neurologylive.comneurologylive.com

Alzheimer Vaccine ABvac40 Shows Potential to Slow Cognitive Decline in Phase 2 Study

Data presented at AAIC 2025 from a phase 2 study suggest that ABvac40 may slow cognitive decline in patients with Alzheimer disease, particularly among those who developed higher antibody levels.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

neurologylive.com broke the news in on Monday, August 4, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Alzheimer's Disease icon

Alzheimer's Disease

News
For You
SearchBlindspotLocal